Treatment of childhood acute lymphoblastic leukaemia (ALL) has improved considerably in
recent years. A contributing factor has been the improved stratification for treatment …

The process of malignant transformation in paediatric acute leukaemias is complex,
requiring at least two deleterious events resulting in DNA damage. This damage ranges …

Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute
lymphoblastic leukemia revealed 29 of 207 cases (14%) with markedly elevated expression …

To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute
lymphoblastic leukemia (ALL), a clinically defined poor-risk group with few known recurring …

The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL)
remains poor, in part from a lack of therapeutic targets. We identified the type I cytokine …

We report gene expression and other analyses to elucidate the molecular characteristics of
acute lymphoblastic leukemia (ALL) in children with Down syndrome (DS). We find that by …

High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell
acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation …

JAK2 kinase inhibitors were developed for the treatment of myeloproliferative neoplasms
(MPNs), following the discovery of activating JAK2 mutations in the majority of patients with …

Recent genomic studies have shown that copy number abnormalities (CNA) of genes
involved in lymphoid differentiation and cell cycle control are common in B‐cell precursor …

Newborns and children with Down syndrome (DS) often present with congenital transient
leukemia and have an increased risk of acute myeloid leukemia and acute lymphoblastic …